MedPath

Examining the role of serum periostin as a prognostic marker of asthma

Not Applicable
Conditions
asthma
Registration Number
JPRN-UMIN000030674
Lead Sponsor
Kyoto University
Brief Summary

High serum periostin levels at baseline may predict future requirement for highly intensive asthma treatment for type-2 inflammation, i.e., the need for increasing high dose ICS, SCS use or omalizumab. In "Assessment of serum periostin level as a predictor of requirement forintensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort".

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
78
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who expressed a denial of secondary use to other research.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath